Navigation Links
Positive Clinical Data for TASQ - Active Biotech's Novel Treatment,of Prostate Cancer

LUND, Sweden, March, 9, 2007-Active Biotech (ACTI.ST), today announced new positive clinical data from the Phase Ib study of TASQ, for the treatment of prostate cancer.

By step-wise dose escalation, a safe dose of 1 mg/day of TASQ was achieved, which corresponds to a doubling of the previously reported maximum tolerated dose (MTD) level of 0.5 mg/day. This means that a step-wise intra-patient dose-escalation enables a dose of 1 mg/day to be administered in future clinical trials.

"These new results confirm and reinforce earlier results obtained at a lower dose level. We now have a very complete data set that constitute a solid base to move into Phase II clinical trials", said Sven Andréasson, President and CEO of Active Biotech.

The ongoing 10-week study comprises patients with so called hormone-refractory prostate cancer. This is an advanced stage of prostate cancer where the tumor cells no longer respond to hormone treatment. All patients entering the study had rising serum levels of Prostate Specific Antigen (PSA), which is a surrogate marker for tumor progression.

PSA measurements were recorded and PSA velocity (PSAV) was calculated after 28 days of treatment. Five out of six patients had a >50% decrease in PSA velocity compared to prior treatment. Three of these five patients exhibited a decrease in absolute PSA levels.

The study is being performed at the urological clinics at the University Hospitals in Lund, Malmö and Uppsala, Sweden.

The objective of the TASQ project is to develop a pharmaceutical product that can be administered orally for the long-term treatment of prostate cancer. Phase II studies are scheduled to start during 2007. The Medical Products Agency has approved on the new MTD to be used in the continued clinical program of TASQ.

The pharmaceutical market for prostate cancer is estimated at more than USD 3 billion a year. Prostat
'"/>




Page: 1 2

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/28/2015)... July 28, 2015 At the ... Experience Association recognized 15 winners in the categories ... applied across multiple vertical markets. ContextMedia:Health proudly ... Award for its success with its first-to-market ... ContextMedia:Health, the leading provider of digital ...
(Date:7/28/2015)... July 28, 2015 Transparency Market Research ... " Cancer Diagnostics Market - Global Industry Analysis, ... " . According to this report, the global cancer diagnostics ... during the forecast period of 2014 to 2020. In 2013, ... and is expected to be worth US$168,649.3 million by 2020.The ...
(Date:7/28/2015)... CONSHOHOCKEN, Pa. , July 28, 2015 ... the keynote address at Good Neighbor Pharmacy,s 2015 ... 29 to Aug. 1 in Las Vegas, Nev. ... on CNN,s television-show, "Somebody,s Gotta Do It," and Discovery Channel,s, ... country to celebrate the nation,s  "unsung heroes" – people whose ...
Breaking Medicine Technology:ContextMedia:Health Receives Top Award at the ICX Association Excellence Awards 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 2Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 3Cancer Diagnostics Market is Expected to Grow at CAGR of 7.6% From 2014 to 2020, to be Worth US$168,649.3 Million by 2020: Transparency Market Research 4Mike Rowe to Address Community Pharmacists at ThoughtSpot 2015 2
... THE WOODLANDS, Texas, Dec. 6, 2011 The US Oncology ... M.D., New York Oncology Hematology , and J. Russell ... discussion with oncologists on value-based reimbursement and its impact on the ... Dec. 13 at 1:00 p.m. ET/ 12 p.m. CT/ 11 a.m. ...
... and AMSTERDAM, Dec. 6, 2011 Agendia, an ... of formalin fixed, paraffin embedded tissue technology applied ... Delivering Agendia,s tests in a paraffin embedded tissue ... the superior science, development and validation found in ...
Cached Medicine Technology:The US Oncology Network to Present Webinar on Value-Based Reimbursement 2Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue 2
(Date:7/28/2015)... ... July 28, 2015 , ... Darryl Worley’s ... volunteers celebrate the 14th year of raising money for the Darryl Worley Foundation. ... for this year’s main concert Saturday, Oct. 3. , This year’s concert will ...
(Date:7/28/2015)... ... July 28, 2015 , ... The Denver ... of Philanthropy Reframed and Exhibited,” a photographic and narrative exploration of African American ... historic Five Points neighborhood. , Denver is one of only ten cities to ...
(Date:7/28/2015)... ... July 28, 2015 , ... By 2016, the number of ... to engage with customers on a highly personal basis, increasing customer loyalty. However, capitalizing ... big growth opportunities or lose customers to more nimble competitors. , The Open Mobile ...
(Date:7/28/2015)... ... 2015 , ... Morristown Medical Center, part of Atlantic Health System, today announced ... hospitals in the nation, to implant the newly approved CoreValve® Evolut® R System from ... in good condition. , The CoreValve® Evolut® R System was approved by the U.S. ...
(Date:7/28/2015)... , ... July 28, 2015 , ... Dr. Edward ... arrival of Dr. Sudeep Roy in July 2016. Coming to Austin from Philadelphia, ... Dr. Buckingham. The twelve-month long training is facilitated annually by the American Academy ...
Breaking Medicine News(10 mins):Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 2Health News:Worley’s 14th Tennessee River Run Will Host Wade Hayes, Lorrie Morgan, Tracy Lawrence and Others 3Health News:"The Soul of Philanthropy Reframed and Exhibited” Comes to Denver 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 2Health News:Open Mobile Media: Etsy, Google, The Weather Company, CBS, TaskRabbit and New York Times: Moving from Web to Mobile-First 3Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 2Health News:Morristown Medical Center First Hospital in New Jersey to Implant Newly Approved Heart Valve 3Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 2Health News:Buckingham Center for Facial Plastic Surgery Welcomes Fellow 3
... Launch New Accreditation Program This Spring, LOVELAND, ... (PHII), a non-profit 501(c)(3) organization that promotes,credible, transparent, ... announces the election of Joel V.,Brill, MD; Garry ... to the PHII,Board of Directors. They will join ...
... was announced that the,U.S. Court of Federal Claims ... favor of a child who regressed into autism ... the mercury-based preservative,thimerosal., Case documents state that ... underlying condition that ultimately led to,regressive encephalopathy and ...
... the University of Minnesota and North Carolina State University ... friendship and companionship they also share the same ... the researchers say that because of the way the ... some humans and dogs. , Jaime Modiano, V.M.D., Ph.D., ...
... The distinctive ability of mothers to identify the cries ... is critical to the survival of these offspring. In ... to recognize and respond to the smiles and cries of ... and social development of these babies. We have had ...
... Blue Cross and Blue,Shield,s Member Health Index has ... of the Blue Cross and Blue Shield Association, ... Shield companies are,working to increase the efficiency and ... Department of Health Care Policy,evaluates submissions from participating ...
... the full line of dermatologist endorsed moisturizers, ... the,makers of a full line of dermatologist endorsed ... skin conditions, is launching its 2008,"Prepare to Unveil ... looking and beautiful skin. Four Theraplex(R) solutions:,HydroLotion, ClearLotion, ...
Cached Medicine News:Health News:Population Health Impact Institute Announces New Board Members 2Health News:Government Concludes Vaccines Caused Autism 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 3Health News:Maternal love: How a mother's brain responds to her infant 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 2Health News:Anthem Blue Cross and Blue Shield's Member Health Index Named BlueWorks(R) Award Winner 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 2Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 3Health News:Prepare to Unveil Yourself with Theraplex(R) for Spring and Summer 2008 4
... critical patients more waveforms, 12-Lead ECG, ... package and cardiac output bundled into ... with your patients., We use quick-action ... which means less time spent looking,through ...
... comfort. The Nylon Finger Trap are gentle on ... Nylon Finger Traps create a complete upper extremity ... Digi Grip or ISI Advanced Universal K Table. ... packs and come in five sizes: Extra-small, small, ...
... FH system uses a ... infrastructure operating in ... communication of patient information. ... of up to 640 ...
Spacelabs offers an approach that allows your telemetry and step-down units to configure systems to meet their telemetry requirements. Our modular telemetry system data are integrated into the depart...
Medicine Products: